Supplements reduce risk among children with low serum 25(OH)D and have beneficial effects in children with atopic dermatitis, allergic rhinitis

Thermal images taken in home settings at week 0 can discriminate healed from unhealed leg venous ulcer wounds

Patients aged 45 years or older at diagnosis more likely to have serious persistent erythema and telangiectasia

No one product is superior for all categories; more of an increase seen in lip heig

Students pursuing dermatology have lower odds of intending to care for underserved populations, practice in underserved areas

Progression-free survival prolonged with relatlimab nivolumab versus nivolumab alone for previously untreated advanced melanoma

Incidence rates of atopic dermatitis and bacterial skin infections higher among urban-living Indigenous children and young people in high-income countries

Mepivacaine found to be noninferior versus lidocaine for pain relief and bilateral wrinkle improvement

Researchers find no evidence that vitamin D supplementation reduces incidence of keratinocyte cancer

Younger age at diagnosis, Clark level II linked to low risk for death among patients with stage I lesions, negative clinical nodes

Monkeypox virus infection among <18s accounted for 0.3 percent of reported cases; most children were not hospitalized

Transmission detected up to a maximum of four days before onset of symptoms

Static Physician's Global Assessment response maintained for those continuing apremilast, receiving apremilast after placebo

Odds ratios for serum dupilumab levels at 16 weeks predicting long-term response and adverse events not significant

Confounding variables, particularly comorbidities, impact association

In phase 2 study, relatlimab and nivolumab combination immunotherapy resulted in pathologic complete response rate of 57 percent

Increase in adjusted rate of clinic visits for itch and atopic dermatitis seen during week with versus without wildfire among adults aged 65 years...

17.2 percent of patients had at least one return emergency department visit within 30 days, while 2.4 percent had a dermatology visit

Current evidence is insufficient for assessing balance of benefits and harms of screening for asymptomatic teens, adults

Robust antitumor activity and good tolerability observed in phase 2 study of nivolumab for first-line treatment of advanced cutaneous squamous cell carcinoma

More patients receiving ruxolitinib have decrease of at least 75 percent from baseline in facial Vitiligo Area Scoring Index

Response-adapted de-escalation of immunotherapy yielded incremental net monetary benefit of $28,849 versus standard of care

Main reason for stopping minoxidil is lack of effectiveness